ArticleInternal and emergency medicine2026
Altered global longitudinal strain is a common finding in liver transplant recipients with mild cardiometabolic burden.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplant (LT) recipients represent a population at elevated cardiovascular (CV) risk, yet conventional assessment tools often fail to capture early myocardial dysfunction. Global longitudinal strain (GLS) has emerged as a sensitive marker of subclinical myocardial dysfunction, although its role in the long-term post-transplant setting remains poorly defined. The study aimed to evaluate left ventricular (LV)-GLS in a population of stable LT recipients with a mild cardiometabolic burden and to explore possible associations with metabolic, lifestyle, inflammatory, and transplant-related variables. A secondary aim was to assess longitudinal GLS variation over a 12-month period. We conducted a cross-sectional observational study in 40 LT recipients. Cardiometabolic parameters, body composition (including bioimpedance analysis), diet (Medi-Lite), physical activity (IPAQ), echocardiography, and levels of circulating inflammatory cytokines were measured. CV risk scores were calculated. GLS impairment was detected in 47.5% of patients, despite preserved ejection fraction. Antihypertensive therapy correlated with more favorable GLS, whereas higher IL-17A and IL-1β levels were paradoxically linked to preserved strain. No association was found with immunosuppressive regimen or lifestyle indices. GLS remained unchanged at 12 months, irrespective of weight loss or dietary improvement. GLS appears more sensitive than EF in detecting subclinical myocardial dysfunction in LT recipients, highlighting its potential role in post-transplant CV surveillance. Antihypertensive treatment may exert protective effects, whereas cytokine patterns suggest unconventional mechanisms of cardiac modulation. Larger longitudinal studies are needed to confirm prognostic implications and integrate GLS into CV risk stratification pathways post-LT.
Indexed as
Identifiers
42286334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.